Home
Life Sciences

Sector: Life Sciences

Huawei, Intel among big firms selling patents in June-recorded transactions

Two deals could bring NPE risk but others stem from bankruptcies, buying and selling of business units and company product collaborations

Historic moment as UPC hands down two full decisions within 24 hours of each other

The Unified Patent Court has handed patentees a win and a loss in its first on-the-merits rulings

Pharma patent litigation highlights in Southeast Asia in early 2020s

Rouse highlights some of the most important pharma patent decisions issued by Southeast Asian courts in the past four years

Latest content

Watershed moment as preliminary injunction granted in US biosimilar dispute

Regeneron’s PI against Samsung Bioepis in ongoing aflibercept litigation follows several failed attempts to obtain interim bans by biologic patentees

18 June 2024

Three crucial lessons to navigate IP and regulatory devils in medical innovation

Advice for biotech-pharma innovators to manage IP strategy while taking the risky gamble of introducing new drugs or medical devices to market

14 June 2024

Consolidating related cases in the Western District of Texas just got harder

Chief Judge Alia Moses’ new requirement to file a motion with legal, factual justification prior to case consolidation is “a solution in search of a problem”, one attorney says

12 June 2024

Delhi High Court’s reversal of Novartis injunction provides further guidance on India’s controversial Section 3(d) requirement

Pendulum swings in favour of local generic drugmaker Natco in long-running Indian pharma dispute against Novartis

12 June 2024

Bristol-Myers wins one and loses one in Europe-wide Eliquis war

The wildly inconsistent decisions produced by the region’s national courts underscore the potential appeal of the Unified Patent Court

07 June 2024

How the UPC reshaped global enforcement strategies in its first year

Everything you need to know about year one of Europe's new patent system

05 June 2024

Software assets dominate market: patent transactions in Q1 2024

AST reports that deal numbers were influenced by economic conditions, trends in litigation funding, licensing cycles, and operating companies selling non-core assets

04 June 2024